Luděk Sojka graduated in Molecular and Cellular Biology at the Faculty of Science, Charles University Prague and gained his PhD in 2011.  His professional career extends from the Czech Academy of Sciences at the Institute of Molecular Genetics and the Institute of Microbiology, where he studied the molecular mechanisms of protein synthesis and regulation of transcription. Since 2011, he has continued to study the molecular mechanisms of human cancer diseases at the Department of Immunology, 2nd Medical Faculty at Charles University in Prague.

Luděk is a cell therapy professional, active in the field for more than 10 years. At Sotio, he held the positions of COO and CTO where he was responsible for both SOTIO GMP facilities in Prague, Czech Republic and Beijing, China including manufacturing of cell therapy products, quality control, logistics and process development along with leadership of technology transfers. Following the formation of SCTbio Luděk was appointed to the position of Chief Executive Officer. He joined PPF Biotech network in 2011.